8-K
filed March 13, 2025, 7:59 PM ET
ticker STRO
CIK 0001382101
other material
confidence high
sentiment negative
materiality 0.85
SUTRO BIOPHARMA, INC. (STRO): restructuring charge — Sutro restructures with 50% layoffs, deprioritizes luvelta; CEO Newell steps down, Jane Chung appointed
SUTRO BIOPHARMA, INC.
- Jane Chung appointed CEO, replaces Bill Newell effective March 13, 2025; CFO and CMO also transitioning.
- Workforce reduced ~50%; luvelta (STRO-002) development halted; out-licensing sought.
- Cash, cash equivalents & marketable securities $316.9M as of Dec 31, 2024; cash runway into at least Q4 2026.
- Restructuring costs estimated $40-$45 million, largely in 2025; revenue $62M in FY2024 vs $153.7M in 2023.
- Three IND filings planned over next 3 years: STRO-004 (Tissue Factor ADC) expected 2H 2025, STRO-006 in 2026, dual-payload ADC in 2027.
Key facts
Extracted from this filing and checked against the source text.
Executive change
SEC 8-K Item 5.02
confidence 1.0
William J. Newell resigned as Director at SUTRO BIOPHARMA, INC..
- Action
- resigned
- Role
- Director
Exact text from the filing
resigned as a director of the Board, effective as of the Newell Separation Date
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
William J. Newell resigned as President and Chief Executive Officer at SUTRO BIOPHARMA, INC..
- Action
- resigned
- Role
- President and Chief Executive Officer
Exact text from the filing
Mr. Newell ceased his role as the Company’s President and CEO, effective March 13, 2025
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Jane Chung was appointed as Class II Director at SUTRO BIOPHARMA, INC..
- Action
- appointed
- Role
- Class II Director
Exact text from the filing
The Board also appointed Ms. Chung as a Class II Director of the Company, effective as of the Newell Separation Date.
View on SEC.gov
Executive change
SEC 8-K Item 5.02
confidence 1.0
Jane Chung was appointed as Chief Executive Officer at SUTRO BIOPHARMA, INC..
- Action
- appointed
- Role
- Chief Executive Officer
Exact text from the filing
Effective as of the Newell Separation Date, the Board appointed Jane Chung, the Company’s President and Chief Operating Officer, to succeed Mr. Newell as Chief Executive Officer.
View on SEC.gov
Restructurings & Charges
SEC 8-K Item 2.05/2.06
confidence 0.9
SUTRO BIOPHARMA, INC. announced a restructuring with charges of approximately $40 million to $45 million affecting luveltamab tazevibulin (luvelta) activities and internal GMP manufacturing facility (approximately 50%).
- Type
- restructuring
- Charge
- approximately $40 million to $45 million
- Affected area
- luveltamab tazevibulin (luvelta) activities and internal GMP manufacturing facility
- Headcount
- approximately 50%
Exact text from the filing
The total cash payments and costs related to deprioritizing luvelta-related activities and reducing the workforce are estimated to be approximately $40 million to $45 million, with a significant majority of these amounts expected to be paid in 2025.
View on SEC.gov
This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice.
See methodology for how this pipeline works.